Effectiveness of a Digital Therapeutic for Enhancement of the Quality of Life of People with Cancer (lancivis): a randomized controlled trial

Effectiveness of a Digital Therapeutic for Enhancement of the Quality of Life of People with Cancer (lancivis): a randomized controlled trial - DELCA-trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

DRKS

Registry ID

DRKS00027057

Enrollment

604

Registered

2021-11-10

Start date

2021-12-21

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C00-C97

Interventions

Group 1: Intervention group: access to the online program lancivis for 180 days in addtion to care as usual Group 2: Controll group: care as usual

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: diagnosis of cancer (ICD-10: C00 – C97, verified by physician’s document) impaired quality of life (FACT-G total score = 81) consent to participation

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Health-related Quality of Life Assessed via the Functional Assessment of Cancer Therapy – General questionnaire (FACT-G) at T1 (3 months after baseline assessment)	—

Secondary

Measure	Time frame
Depression, Stress, Anxiety, assessed via the Depression-Anxiety-Stress-Scales (DASS-21); Cancer-related Fatigue, assessed via the Chalder Fatigue Scale (CFQ-11); at T1 (3 months after baseline assessment)	—

Countries

Germany

Contacts

Public ContactAnja Specht

GAIA AG

anja.specht@gaia-group.com+4940349930374

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026